Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors

Indiana University logo

Indiana University

Status

Completed

Conditions

Fear
Malignant Tumor of Breast
Cancer of Breast
Breast Cancer
Mammary Cancer
Spontaneous Neoplasm Regression
Breast Neoplasms
Human Mammary Carcinoma
Anxiety
Mammary Neoplasm, Human
Regression, Spontaneous Neoplasm
Spontaneous Neoplasm Remission
Malignant Neoplasm of Breast
Mammary Carcinoma
Breast Carcinoma
Remission, Spontaneous Neoplasm
Neoplasm Remission, Spontaneous

Treatments

Behavioral: Survivorship Education
Behavioral: Acceptance and Commitment Therapy
Behavioral: Enhanced Usual Care

Study type

Interventional

Funder types

Other

Identifiers

NCT02611544
IUSCC-0563

Details and patient eligibility

About

Fear of cancer recurrence (FCR) is one of the most prevalent, persistent, and disruptive sources of distress for adult cancer survivors. Prevalence rates for FCR have been estimated at up to 89%, with approximately half of cancer survivors reporting clinically significant levels of FCR. Despite the recognized prevalence, persistence, and suffering associated with FCR, effective and accessible treatments for FCR are lacking and urgently needed. Our long-term goal is to develop, evaluate, and implement effective behavioral interventions for cancer survivors suffering with FCR.

Full description

The proposed randomized pilot study will assess the effects of a novel therapeutic intervention-Acceptance and Commitment Therapy (ACT)-for breast cancer survivors (BCS) with clinically-significant FCR. ACT is a spiritually-sensitive behavioral therapy that has shown efficacy in the treatment of anxiety in non-cancer populations, and preliminary efficacy in improving a variety of outcomes among adults with cancer. ACT uses mindfulness and acceptance processes, along with committed behavior change in service of an individual's deeply held values to enhance psychological flexibility and encourage adaptive coping with life challenges, such as cancer. The primary objective of the proposed 3-arm randomized controlled pilot trial is to assess the feasibility/acceptability and determine preliminary effect size estimates of ACT in preparation for a fully-powered efficacy trial. To allow for potential drop out (15% attrition) and ensure we have a minimum of 78 completers through the end of the trial, we will enroll approximately 91 BCS with clinically significant FCR (defined by score ≥ 13 on Fears of Cancer Recurrence Inventory-Short Form). Participants will be randomized to one of three groups: (1) a 6-week ACT intervention group (n=26); (2) a 6-week survivorship education group (SE; n=26); or (3) enhanced usual care (EUC; n=26). The impact of ACT, SE, and EUC on survivors' FCR and associated psychological, spiritual, and biological (telomere length) outcomes will be examined at baseline (T1), post-intervention (T2), and at 1-month (T3) and 6-month follow-up (T4) with the following specific aims: Aim 1: Evaluate feasibility and acceptability of ACT, SE, and EUC according to the: Percentage of eligible BCS who consent to participate in the trial; Attendance rate across 6 sessions of ACT and SE; Retention rate through T4 in the ACT, SE, and EUC arms; Mean ratings across groups for intervention satisfaction and helpfulness for managing FCR. Aim 2: Determine pairwise effect size estimates of ACT, SE, and EUC effects at each time point (T2, T3, T4) adjusted for T1 on the: Primary outcome: reducing FCR; Secondary psychological outcomes: cancer-related experiential avoidance, cognitive avoidance, anxiety, depression, post-traumatic stress symptoms, vitality, breast cancer self-efficacy, and quality of life; Secondary spiritual outcomes: spiritual well-being and mindfulness; Secondary biological outcome: telomere length.

Enrollment

91 patients

Sex

Female

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Participants in this study will be eligible if they are:

  • ≥18 years old,
  • have been diagnosed with non-metastatic breast cancer (stages I-III),
  • have completed curative treatment for breast cancer,
  • have not experienced a cancer recurrence, and
  • report a clinically significant level of FCR (Fear of Cancer Recurrence Inventory-Short Form score of ≥ 13)

Exclusion Criteria: Participants in this study will be ineligible if they are:

  • severe depression (PHQ-8 score of ≥ 20),
  • past participation in ACT or formal mindfulness training, and
  • limited English proficiency.

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

None (Open label)

91 participants in 3 patient groups

Acceptance and Commitment Therapy
Active Comparator group
Description:
6 weeks, the ACT group will meet weekly for 2 hours at one of three facilities.
Treatment:
Behavioral: Acceptance and Commitment Therapy
Survivorship Education
Active Comparator group
Description:
6 weeks, SE group will meet weekly for 2 hours at one of three facilities.
Treatment:
Behavioral: Survivorship Education
Enhanced Usual Care
Active Comparator group
Description:
Continue to meet with their health care team + receive a variety of readings at each data collection point on coping with common survivorship concerns, including a booklet from the National Cancer Institute entitled "Facing Forward: Life After Cancer Treatment."
Treatment:
Behavioral: Enhanced Usual Care

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems